I posted a conservative valuation over at stocktwi

Quote:

---

There are a whole lot of unknown variables at this point. Best case scenario is Cytodyn gets overseas distribution deals with a very good percentage split and retains distribution in the U.S. for itself. After first approval and revenue it starts piling up trials for many indications. With all current shares on the market at 5-6 years after first approval conservatively $300 a share. If they really launch trials hard it could be quite a bit more.

---